Levobupivacaina Bioindustria L.I.M. (Levobupivacaine Hydrochloride)

Levobupivacaina is a local anesthetic used in the epidural pathway to achieve targeted nerve blockade.

• Epidural anesthesia: provides surgical anesthesia for lower body procedures.
• Post‑operative analgesia: delivers prolonged pain relief after surgery.
• Labor analgesia: offers effective pain control during childbirth.

• Levobupivacaina Hydrochloride reversibly blocks voltage‑gated sodium channels on neuronal membranes, preventing the initiation and propagation of action potentials. This inhibition stops nerve impulse transmission, resulting in loss of sensation in the targeted area without affecting motor function at appropriate concentrations.

Levobupivacaina may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

• Hypotension: transient drop in blood pressure after epidural administration.
• Bradycardia: slowed heart rate in some patients.
• Nausea: mild to moderate feeling of sickness.
• Pruritus: itching at the injection site or generalized.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm requiring monitoring.
• Central nervous system toxicity: seizures or altered mental status in overdose.
• Allergic reaction: rash, urticaria, or anaphylaxis in hypersensitive individuals.

When using Levobupivacaina, clinicians should consider several safety measures.

• Patient assessment: evaluate cardiovascular and respiratory status before administration.
• Dose titration: use the lowest effective dose to achieve desired analgesia.
• Monitoring: continuously observe blood pressure, heart rate, and oxygen saturation during epidural infusion.
• Contraindications: avoid in patients with known hypersensitivity to amide local anesthetics.
• Drug interactions: review concomitant medications that may potentiate cardiac effects.
• Store at room temperature: keep in original packaging, protect from light and moisture.

Levobupivacaina can interact with other agents that affect cardiac conduction or central nervous system function.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): may increase risk of severe arrhythmias.
• CNS depressants (e.g., benzodiazepines, opioids): can potentiate central toxicity.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance bradycardia.
• Calcium channel blockers: could augment hypotensive effects.
• MAO inhibitors: may increase risk of serotonin syndrome when combined with certain analgesics.